Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia
Arrowhead to release earnings and hold conference call on February 4 2021
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)